All In Biotech

Drug Trial Radar · NCT03714672

Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction

A Randomized, Double-blind, Multi-site, Comparator-controlled, Phase III Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Tramadol Hydrochloride and Diclofenac Sodium in Acute Moderate to Severe Pain After Third Molar Extraction

Last checked: Nov 19, 2026Latest source record: Jul 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,151 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,151

Actual

Start

Aug 26, 2017

Primary completion

Mar 9, 2018

Study completion Mar 22, 2018

Sponsor

Lead sponsor
Grünenthal GmbHIndustry
Sponsor type
Industry
Collaborators
Grünenthal, S.A.
First posted
Oct 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated a new drug fixed-dose combination tablet (FDC) called tramadol/diclofenac at two different strengths (fixed doses of 25 milligrams \[mg\] of tramadol and of diclofenac or of 50 mg each). Tramadol and diclofenac each relieve pain, but they do so by different mechanisms. They were used alone as comparator drug in this study. Both are marketed drugs and are standard treatment for acute pain, including wisdom tooth removal.

Conditions

  • Acute Pain

Interventions

  • Tramadol/Diclofenac 50/50Drug

    Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.

  • Tramadol/Diclofenac 25/25Drug

    Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.

  • Tramadol 50Drug

    Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.

  • Diclofenac 50Drug

    Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain Relief Expressed as Total Pain Relief (TOTPAR) Over the 4 Hours Post-dose Period (TOTPAR4)Time frame: Up to 4 hours after first dose

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Private Clinic

    Aguascalientes, Mexico

  • Private Clinic

    Chihuahua City, Mexico

  • Private Clinic

    León, Mexico

  • Private Clinic

    Puebla City, Mexico

  • University

    San Luis Potosí City, Mexico

  • Private Clinic

    Zapopan, Jalisco, Mexico

  • Private Clinic

    Monterrey, Nuevo León, Mexico

  • Private Clinic

    Monterrey, Nuevo León, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.